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AbstrAct
Current therapy of osteosarcoma (OS), the most common primary bone 
malignancy, is based on a combination of surgery and chemotherapy. Multidrug 
resistance mediated by P-glycoprotein (P-gp) overexpression has been previously 
associated with treatment failure and progression of OS, although other mechanisms 
may also play a role. We considered the typical acidic extracellular pH (pHe) of 
sarcomas, and found that doxorubicin (DXR) cytotoxicity is reduced in P-gp negative 
OS cells cultured at pHe 6.5 compared to standard 7.4. Short-time (24–48 hours) 
exposure to low pHe significantly increased the number and acidity of lysosomes, and 
the combination of DXR with omeprazole, a proton pump inhibitor targeting lysosomal 
acidity, significantly enhanced DXR cytotoxicity. In OS xenografts, the combination 
treatment of DXR and omeprazole significantly reduced tumor volume and body weight 
loss. The impaired toxicity of DXR at low pHe was not associated with increased 
autophagy or lysosomal acidification, but rather, as shown by SNARF staining, with 
a reversal of the pH gradient at the plasma membrane (∆pHcm), eventually leading to 
a reduced DXR intracellular accumulation. Finally, the reversal of ∆pHcm in OS cells 
promoted resistance not only to DXR, but also to cisplatin and methotrexate, and, to 
a lesser extent, to vincristine. Altogether, our findings show that, in OS cells, short-
term acidosis induces resistance to different chemotherapeutic drugs by a reversal of 
∆pHcm, suggesting that buffer therapies or regimens including proton pump inhibitors 
in combination to low concentrations of conventional anticancer agents may offer 
novel solutions to overcome drug resistance.
INtrODUctION
Osteosarcoma (OS) is the most common primary 
malignancy of bone [1]. Since the introduction of 
multiagent chemotherapy to surgical removal of the 
primary lesion, the 5-year survival of OS patients has 
significantly improved, although 30–40% of localized 
OS and over 70% of metastatic OS do not respond to 
therapy and develop pulmonary metastases [2]. The 
mechanism of resistance to chemotherapy has been 
extensively investigated in OS [3–5]. Most studies have 
focused on pathways modulating cancer cell sensitivity, 
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such as the transmembrane ATP-dependent efflux pump 
P-glycoprotein (P-gp) [3–6], Her-2/ERBB2 [7], the 
Bcl-2 family proteins [8], and, more recently, miRNAs 
[9, 10]. On this respect, however, the role of tumor 
microenvironment (TME), a key player for tumor cell 
survival at the primary lesion and the receptive soil for 
cancer cell seeding at distant sites for the (pre)-metastatic 
niche [11, 12], has been neglected so far.  In many cancers 
[13–17], including OS [18, 19], a number of TME-
dependent factors may play a key role in chemoresistance, 
including the modification of the extracellular matrix, the 
recruitment of stromal cells, and hypoxia. The hypoxic 
TME of OS, an osteogenic malignancy usually arising 
in bone, may be particularly relevant for tumor behavior. 
In fact, bone is per se a hypoxic tissue with an oxygen 
tension between < 1% in hypoxic region and < 6% in 
proximity of sinusoidal cavities [20], and it is well known 
that hypoxia controls a number of relevant bone tissue-
specific activities, including angiogenesis, recruitment 
of stem precursors, proliferation, and differentiation of 
committed osteogenic elements [21]. Tumor cells cope 
with hypoxia by switching from aerobic respiration 
to glycolysis, in turn producing lactic acid and causing 
extracellular acidosis [22]. In several malignancies, the 
increased reliance on glycolysis to produce energy occurs 
even in the presence of sufficient oxygen supply [23, 24]. 
Indeed, the extracellular pH (pHe) of different tumor 
types, including sarcomas, ranges from 6.4 to 7.3, whereas 
the pHe of normal tissues is in the range of 7.2–7.5 [25]. 
Locally and acutely, intratumoral pH varies from one 
area to another, showing a trend of decrease that in the 
long term (chronically) results into an average persistent 
intratumoral acidosis. Indeed, pH can locally and rapidly 
change due to a short-lived phenomenon, like to apoptosis 
of a small group of cells, to temporary hypoxia due to 
the disruption of  small vessels, or to temporary high 
glycolytic activity [26, 27]. As a result, in the tumor 
TME, acidosis is both chronic and acute, with different 
grading. We have recently demonstrated in sarcomas that 
a low pHe is linked to malignant behavior [28, 29]. In 
other cancers, acidity has also been associated with drug 
resistance [30–32]. 
In this study, we studied the role of pH regulation 
on drug resistance of OS. For this purpose, in wild type 
OS cells we investigated doxorubicin (DXR) cytotoxicity 
and intracellular accumulation under acidic conditions, 
the role of lysosomal acidification and autophagy on drug 
resistance, and the effects of lysosomal pH modification 
both in vitro and in vivo. We investigated on the effect 
of rapid changes in pH on drug effectiveness. Our results 
show that, besides P-gp overexpression, extracellular 
acidity is another major player of resistance to DXR, 
suggesting the use of pH modifiers as novel therapeutic 
tools to increase the efficacy and reduce toxicity of 
conventional anticancer agents.
rEsULts
the acidic tME of Os is associated with 
resistance to DXr
As proof-of-principle that our in vitro models were 
representative of the acidic TME of OS, we verified if 
the preselected pHe (culture medium at pH 6.5–7.4–8.0) 
at the beginning of the culture, with or w/o DXR, was 
maintained over the incubation period. We checked the 
pH of medium at different time points for all the OS 
cell lines included in this study and it was very similar 
between the different cell lines. After 72 h, the pHe was 
slightly decreased, possibly due to the high number of sub-
confluent cells. However, the specific pHe values were 
stable over the culture period (Figure 1A, representative 
values only for HOS cells). As expected, due to its cationic 
nature, DXR induced a trend of a slight increase in pHe at 
all conditions. In unbuffered medium, HOS cells secreted 
an amount of protons that, combined with the 5% of 
atmosphere CO2, induced a pHe of around 6.8 (at 48 h: 
6.76 ± 0.09, n = 6, Figure 1A). 
We then sought to investigate whether the reduced 
cytotoxicity of DXR under an acidic TME was present in 
OS cells, even if they do not express P-gp, as previously 
observed in other cancers [31–33]. Indeed, following 
DXR exposure, the percentage of growth inhibition of 
OS P-gp negative cells calculated by direct cell counting 
significantly correlated with the pH values (Figure 1B). 
By indirect viability test, we also found that, at pHe 6.5, 
the concentration of DXR needed to obtain 60% of growth 
inhibition in the same cells was 10-fold higher than at 
pHe 7.4 (Figure 1C). The same type of indirect test was 
also used to calculate EC50 of DXR at different pH. EC50 
at pH 6.5 was around 2,000–fold higher with respect to 
pH 7.4 in  P-gp negative cells, whereas the expression 
of P-gp in HOS 100-DXR cells that we used as positive 
control for chemoresistance (P-gp positive cells) induced 
an increase of the EC50 value of only 500-fold in respect 
to sensitive (P-gp negative) cells (Table 1). To exclude the 
possibility that the reduced DXR cytotoxicity of OS cells 
cultured at low pHe was due to cell death promoted by 
acidity, we used Annexin-V test. We found no difference 
in apoptosis in untreated HOS P-gp negative cells cultured 
at acidic pH in respect to neutral pH (Supplementary 
Figure S1, CTR), whereas DXR-treated P-gp negative 
cells showed a significantly higher induction of apoptosis 
under neutral pH in respect to cells cultured at pH 6.5 
(Supplementary Figure S1, DXR 50 ng/mL). Interestingly, 
culturing sensitive cells (P-gp negative cells) at acidic 
pHe for 48 h was sufficient to completely impair DXR 
nuclear accumulation (Figure 1D and 1E). Resistance 
to DXR mediated by acidic pHe in sensitive cells was 
not associated with the induction of P-gp expression by 
acidosis since HOS P-gp negative cells were still negative 
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for the expression of P-gp protein also when cultured 
at pH 6.5 for 1 month (Figure 1F, HOS 100-DXR P-gp 
positive cells are the positive control). 
Low pHe enhances lysosomal activity but not the 
autophagic flux 
The doubling rate of OS sensitive (P-gp negative) 
cells cultured under acidity was 1.5–2.6 times slower than 
under standard conditions (Table 2), and this reduced 
doubling rate is possibly partially causing the impaired 
cytotoxicity of DXR. 
We next reasoned to assess the role of lysosomal 
acidification on the acid-induced chemoresistance. 
The number of lysosomes of HOS cells was increased 
and lysosomes appeared also more activated when 
cultured in acidic medium, as shown by the presence of 
a higher number of residual bodies detected by electron 
table 1: Ic50 of DXr for growth inhibition
DXr [ng/mL] R2
pHe 6.5 2303.40 0.9952
pHe 7.4 1.37 0.9978
HOs 100-DXr 505.49 0.9599
Figure 1: chemoresistance induced by low pHe. (A) Measurement of pH of medium buffered at different pH and unbuffered 
(UB), over the culture period; (b) percentage of growth inhibition of osteosarcoma (OS) P-glycoprotein (P-gp) negative cells cultured at 
different pH and treated with Doxorubicin (DXR) (15 ng/mL) by direct cell counting. Growth inhibition was obtained in respect to the 
untreated condition at the respective pH (*p < 0.05 vs pH 7.4 for HOS; #p < 0.05 vs pH 7.4 for Saos-2; §p < 0.05 vs pH 7.4 for MG-63); 
(c) Percentage of growth inhibition of HOS P-gp negative cells at different concentrations of DXR under acidic conditions by viability 
indirect assay (***p < 0.001 vs pH 7.4 at the same concentration; #p < 0.05, ##p < 0.01, and ###p < 0.001 vs not treated at the same respective 
pH); (D) DXR nuclear compartmentalization in HOS P-gp negative cells maintained at different pH for 48 h, observation at the confocal 
microscope (Scale bars = 5 μm). (E) Fluorescence intensity of DXR in the nuclei of OS P-gp negative cells treated with 10 mg/mL DXR 
(****p < 0.0001); (F) western blotting analysis of Pgp expression in HOS P-gp negative cells at different pHe and treated or not treated with 
DXR for 30 days. HOS 100-DXR P-gp positive cells were used as positive control. HOS 100-DXR cells were obtained after continuous 
exposure to DXR for several months at pHe 7.4.  
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microscopy, with respect to the neutral condition 
(Figure 2A). To determine lysosomal pH, cells were co-
stained with Lysotracker and Lysosensor fluorescent dyes 
that showed selective accumulation in the lysosomal 
compartment. Cells cultured under acidic conditions had 
a striking increase in the number of acidic vesicles and 
thus a lower vesicular pH (Figure 2B). To further extend 
these findings, we performed quantitative measurement 
of the intensity of the fluorescence emission spectra of 
Acridine Orange (AO) uptaken by single cells at different 
wavelengths. AO is a probe for measuring pH gradients 
across membranes with particular specification to 
intravesicular acidification. Indeed, MG-63 cells cultured 
in acidic medium showed a shift from the green (alkaline) 
to the red (acidic) emission wavelength, indicating 
acidification of lysosomes (Figure 2C). Furthermore, the 
number of lysosomes per single cell was significantly 
increased (Figure 2C). Lysosomal activity is strongly 
associated with mTOR activity, and the recovery of the 
autophagic flux is associated with the early inhibition 
of mTOR phosphorylation, previously reported to occur 
during acidic stress [34, 35]. Therefore, we investigated 
whether OS sensitive cells under acidic conditions showed 
an altered transcriptome related to the mTOR. This, 
however, was not the case: in fact,  after 24 h we did not 
observe any significant variation of the transcripts related 
to the mTOR pathway (Supplementary Figure S2). 
Staining for the autophagic markers LC3 (green) 
and lysotracker (red) showed the presence of LC3-positive 
lysosomes (Figure 3A). In order to understand how low pH 
modulates autophagy in OS cells, we performed kinetics 
analysis of the autophagic flux in HOS cells after 48 h. 
During autophagy, the cytosolic form of LC3 (LC3-I) is 
lipidated to the autophagosome-associated form (LC3-
II) which is then degraded after fusion with lysosomes. 
Measurement of the autophagic flux is determined by 
the accumulation of LC3-II protein in the presence of 
the lysosomal inhibitor bafilomycin A1 (BafA1) and 
expressed as the ratio of LC3-II signal intensity in cells 
with and without BafA1 and normalized for the actin 
signal [36]. Despite a temporary but minor downregulation 
of the autophagic flux at 4-8 h, cells were fully competent 
for autophagy at 24 and 48 h, as indicated by the similar 
accumulation of LC3-II in the presence of BafA1 in 
the two pH conditions (Figure 3B and Supplementary 
Figure S3). The ability of HOS cells to maintain a high 
self-degradative process after exposure for 24 h at pH 6.5 
was also confirmed by using other lysosomal inhibitors 
(Figure 3C). Since upregulation of the autophagy 
modulator HMGB1 was reported to mediate DXR 
resistance in OS [37], we evaluated the effects of acidosis 
on intracellular HMGB1 levels in HOS cells. Both DXR 
and acidity per se induced the expression of HMGB1 
in HOS cells (Figure 3C and 3D and Supplementary 
Figure S4). Despite this, treatment with DXR did not 
affect the autophagic flux in HOS cells in neither of the 
pH considered (Figure 3D and Supplementary Figure S5). 
In order to study whether the maintenance of autophagy 
in acidic conditions was associated with sensitivity to 
DXR in HOS cells, we performed transient siRNA-
mediated knock-down of Atg5, a gene involved in 
autophagosome maturation. After efficient knockdown of 
Atg5 (Supplementary Figure S6), cells were exposed to 
medium at pH 7.4 or pH 6.5 and treated or not treated 
with DXR. Analysis of cell death showed that inhibition 
of autophagy does not affect the sensitivity to DXR 
under either pHe (Figure 3E). In addition, cells cultured 
at acidic pH maintained DXR resistance independently 
of autophagy. In conclusion, these findings show that 
modulation of autophagy during acidity is not involved in 
DXR resistance of OS cells.
targeting lysosomal activity enhances the DXr 
effectiveness 
To confirm that the autophagy-independent 
lysosomal activity is involved in DXR response after short-
term acidosis, we used omperazole (OME), a proton pump 
inhibitor that targets lysosomal acidification by blocking 
vacuolar-ATPase (V-ATPase) activity in sarcoma cells 
[29, 38]. Treatment with OME enhanced growth inhibition 
promoted by DXR under acidity. Especially in HOS and 
MG-63 sensitive cells, DXR treatment showed a significant 
effect at lower doses, when used in combination with 
OME, with respect to the single treatment (Figure 4A). 
Similar results were obtained in vivo in a xenograft 
model of OS. When both intraperitoneally administered, 
combined treatment with OME (10 mg/kg) enhanced 
the cytotoxic effect of DXR (1.5 mg/kg), resulting in a 
significantly lower tumor volume and a higher necrotic 
index (Figure 4B–4D). Interestingly, mice treated with 
the combination of OME and DXR showed a statistically 
significant reduced loss of body weight compared to mice 
treated with DXR alone (DXR treated group: 20.1 ± 0.6 gr; 
OME + DXR treated group: 22.3 ± 0.6 gr; *p < 0.05), 
possibly suggesting that OME reduced DXR toxicity. 
table 2 : Doubling time of Os cell lines at different pHe
pHe 6.5 pHi 7.4 p
HOS 33.0 ± 0.6 (n = 4) 14.3 ± 0.7 (n = 4) 0.0209
MG-63 72.3 ± 13.8 (n = 5) 28.2 ± 2.7 (n = 4) 0.0143
Saos-2 38.3 ± 2.0 (n = 5) 25.1 ± 4.4 (n = 4) 0.0275
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Altering the pH gradient at the plasma 
membrane is a key mechanism of drug resistance
We then sought to investigate the total amount 
of DXR that effectively enters into the OS sensitive 
(P-gp negative) cells cultured under acidic conditions 
through image analysis (Figure 5A) and flow cytometry 
(Figure 5B). A low fluorescent signal of the drug was 
detected within the cells at acidic pH in respect to neutral 
conditions both at 24 and 48 h (Figure 5B). This finding 
suggests that the major obstacle for DXR effectiveness 
under short-term acidosis is its entrance into the cell 
through the plasma membrane. This is possibly due 
either to a phenomenon known as the partition theory, or 
through a change of membrane stiffness, both related to 
a reversal of the ∆pHcm [33]. To extend this observation, 
we used SNARF staining in living cells and observed 
a significant alteration of ∆pHcm that would result in an 
enhancement of intracellular positive charge with respect 
to the extracellular space (Figure 5C). The alteration of 
∆pHcm showed a trend of reduction in MG-63 cells and a 
significant reduction in Saos-2 sensitive (P-gp negative) 
cells when cells were treated with OME (Figure 5C). 
Interestingly, we found that the same pattern of an altered 
∆pHcm was also present in P-gp expressing resistant OS 
cells cultured in a standard medium at pH 7.4, with respect 
to the sensitive P-gp negative parental cells also cultured 
in standard medium at pH 7.4 (Figure 5D). The use of 
the MDR modifier verapamil produced a decrease of this 
effect, whereas the incubation with a MDR-1 neutralizing 
Figure 2: Lysosomes in cells under acidic conditions are more acidic and increased in number. OS cells were maintained 
for 48 h at different pHe before analyses. (A) trasmission electron microscopy of HOS cells (in the rectangles, a detail of the original 
image is enlarged); (b) lysosensor (green) and lysotracker (red) staining of HOS cells; (c) spectrum analysis of Acridine Orange (AO) 
emission in vesicle-like structure in HOS cells. AO is a probe for measuring pH gradients across membranes with particular specification 
to intravesicular acidification, with a trend of localization and subsequent accumulation and polymer formation (emission at 655 nm) in 
acidic compartment, and of monomer localization at higher pH (emission at 530 nm).  Upper panels: representative graphs of the intensity 
of spectra of all the lysosomes within a cell at the two different pHe; lower panel: representative image of intracytoplasmic area examined; 










 are the green 
(520–540 nm) and the red (645–665 nm) integrated emission intensities, ***p < 0.0001 vs pHe 7.4)], and number of acidic vesicles within 
a cell (*p < 0.05 vs pHe 7.4). 
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antibody significantly impaired this effect, completely 
restoring the original phenotype (Figure 5E). These 
results suggest that chemoresistance mediated also by 
P-gp activity is partially due to pHi regulation. Finally, 
we found that drug resistance promoted by short-term 
acidosis is not specific only to DXR, since the treatment 
with methotrexate, vincristine, and at a lower extent with 
cisplatin was significantly impaired by low pH (Figure 6). 
As a control we used P-gp expressing cells in which a 
very high resistance to DXR and vincristine, and only a 
low resistance to cisplatin and methotrexate were present. 
Notably, drug resistance conferred by short-term acidosis 
was dramatically higher for methotrexate, and less evident 
with vincristine. In the first case, it is likely that BCRP 
cancer resistance proteins that efflux methotrexate out of 
the cells and that are expressed by OS cells [39], transport 
more efficiently the drug at low pH [40]. Regarding 
vincristine, the mild effect of pH 6.5 on resistance is 
Figure 3: Autophagic flux was unaffected in OS cells cultured under acidic conditions. (A) Upper panel: LC3-B 
immunostaining (green), with LysoTracker staining (red), and nuclei staining (blue) under different pH (scale bar 10 μm). Lower panel: 
false color for LC3-B staining showed in the upper panel; (b) analysis of autophagic flux by western blotting of LC3B and SQTSM1 
expression of HOS cells cultured at pH 7.4 and 6.5 at different pH and at different time-points (4-8-24-48- hrs) in presence of absence of 
BafA1treatment (50 nM) for 2 h before collection; (c) western blot analysis of proteins related to the autophagic flux HMGB1 and LC3-II 
in HOS cells cultured at pH 7.4 and 6.5, in presence of BafA1 (50 nM) for 2 hrs before collection, or of the lysosomal inhibitors (L, Pepstain 
A/E64d) treatments at 10 μg/mL, or with complete medium (M); (D) western blot analysis HMGB1, LC3-II, and SQTSM1 in HOS cells 
treated for 24 h with DXR, in presence or absence of BafA1 at different pH (7.4 and 6.5); (E) evaluation of the effect of the silencing of 
autophagic protein ATG5 on HOS cell death, under acidic conditions in HOS cells (*p < 0.05 vs  not treated cells at the respective pH). 
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possibly due to the very acidic pKa of the drug (between 
3.5 and 4.5) that is thus less subject to the reversal of 
∆pHcm .
DIscUssION
Since the time of discovery of MDR mediated by 
P-gp expression [41], the concept of chemoresistance 
has been extensively revised and expanded into two 
major types. Biochemical resistance is mediated by the 
upregulation of drug efflux or metabolic pathways, such as 
MDR-1 or BCRP. Moreover, physiological resistance may 
also occur as a consequence of poor perfusion, hypoxia, 
and/or acidity [42]. 
In this study, we mimicked the acidic conditions of 
extracellular space that are commonly detected in OS as 
a result of the significant anomalies in energy metabolism 
by using in vitro cell culture medium buffered at pH 6.5. 
Under these conditions, we observed that the growth 
inhibition of OS sensitive (P-gp negative) cells induced 
by DXR was significantly impaired. In fact, at pH 6.5, 
a 10-fold increase of DXR concentration was necessary 
to achieve the same level of growth inhibition detected 
at pH 7.4, and the amount of drug that accumulated into 
the nucleus, the main target site of DXR activity, was 
significantly reduced. 
Therefore, the effect of pH on DXR resistance did 
not rely on P-gp expression, and might be attributed to 
different mechanisms. We observed a reduced replication 
rate at pHe 6.5, possibly due to a block in cell cycle 
[43], and this might interfere with the effectiveness of 
an antiproliferative agent, like DXR, blocking type II 
topoisomerase activity [44]. Another possible explanation 
concerns lysosomal acidification. Acidic lysosomes can 
sequester weakly basic molecules, like DXR, to an extent 
that is directly related to the level of acidity [45, 46]. The 
compartmentalization into the lysosomes might derive 
from the transfer of DXR from the cytosol, or from a 
Figure 4: Lysosomal targeting enhanced DXR cytotoxicity. (A) Cells were treated with DXR for 48 h under acidity following 
pretreatment of 2 h with (+ OME) or without (- OME). The percentage of inhibition was obtained by an indirect viability assay (*p < 0.05, 
**p < 0.01, and ***p < 0.001 vs not DXR treated cells, at the respective +OME or – OME condition); (b) percentage of necrotic area 
in a mouse model of OS treated with DXR in combination or not with OME (*p < 0.05 vs non treated group); (c) Tumor volume in 
the same xenografts (*p < 0.05 vs non treated group); (D) ematoxylin & eosin staining of xenograft sections, representative images 
(scale bar = 100 micrometers).
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direct endocytotic process [47]. Compared to standard 
conditions, in OS cells cultured for a few hours in acidic 
medium, we found a higher number of larger lysosomes 
and, as already demonstrated for breast cancer cells [46], 
the lysosomal compartment was also more acidic. 
Closely associated to lysosomal acidification, 
autophagy is an adaptation mechanism that cancer cells 
adopt when exposed to an adverse microenvironmental 
conditions, such as acidity [35, 48] and anticancer agents, 
including DXR [37]. After 24 h exposure to acidity, 
however, we did not observe changes in the expression 
of autophagy-related genes. Such a short endpoint was 
selected to parallel the rapid nuclear uptake of DXR. 
Although treatment with DXR or with acidic pHe 
increased HMGB1 expression, the inhibition of autophagy 
via knock-down of Atg5 did not alter the sensitivity of 
OS cells to DXR at any pHe condition, further suggesting 
that autophagy-mediated DXR resistance is not a general 
phenomenon in OS cells. 
We further investigated the role of lysosomes in 
OS chemoresistance under short-term acidic conditions, 
and independently of autophagy. We have previously 
shown that treatment with OME, a gastric H+/K+-ATPase 
inhibitor that targets also the lysosomal proton pump 
V-ATPase [49], alkalinizes lysosomal pH in sarcoma 
cells [29, 38]. Here, we reasoned to test the effects of 
Figure 5: Total DXR concentration in HOS cells under acidity is reduced due to an increased pH gradient (∆pHcm ) at 
the plasma membrane. (A) 3D intensity embossed and confocal acquisition of DXR fluorescence in the DXR intracellular uptake assay 
by NIS Element software (Nikon) in HOS cells cultured under different pH, representative image (scale bar = 10 μm); (b) cytofluorimetric 
quantification of DXR uptake in HOS cells cultured under different pHe (*p < 0.05 not treated vs the DXR treated, at the same pHe; § p < 0.05 
DXR treated at pHe 6.5 vs the DXR treated at pH 7.4). MFI, Mean Fluorescence Intensity. (c) ∆pHcm plasma membrane gradient by SNARF 
staining of live cells cultured under acidic conditions, treated or not treated with OME, and measured by spectral confocal microscopy 
(****p < 0.0001 vs pHe 7.4, #p < 0.05 vs pHe 6.5, n = 12). The uncharged SNARF-1-AM can passively diffuse across the plasma 
membrane to cytosol, where it hydrolyzed by cellular esterases to free SNARF-1. It is this form that is fluorescent, and is consequently 
the intracellular pH probe. Intracellular pH measurement and pH calibration using single excitation-dual emission fluorescence ratios were 
performed as described in the method paragraph; (D) ∆pHcm plasma membrane gradient by SNARF staining of live resistant cells cultured 
at pHe 7.4 and that express P-gp protein (****p < 0.0001 vs sensitive cultured at pHe 7.4, n = 12); (E) ∆pHcm plasma membrane gradient 
by SNARF staining of live HOS resistant cells (HOS 100-DXR), cultured at pHe 7.4, and treated or not treated with verapamil or with a 
monoclonal blocking antibody against MDR-1 (****p < 0.0001 vs resistant cells).
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OME on DXR sensitivity, both in vitro and in vivo. After 
pretreatment with OME, the growth inhibition of DXR 
was significantly increased. The combination of OME 
with DXR induced a growth rate reduction at a 10-fold 
lower concentration of DXR. In the xenograft model of 
OS, when combined with OME, treatment with DXR 
produced a significant reduction of tumor volume and 
an increase of necrosis. Most importantly, these effects 
were obtained with a low concentration (1.5 mg/kg) of 
DXR with respect to the dosage commonly used in OS 
xenografts (2.5 mg/kg) [50]. DXR as a single treatment 
at the same concentration did not produce any effect. 
Such concentration was calculated as 1/6 of the minimum 
dose used for a therapeutic regimen in human patients 
(60–90 mg/m2, corresponding to 9–14 mg/kg in a child 
of 24 kg, with a height of 120 cm) [1]. The combined 
treatment also had a positive impact on the systemic 
toxicity associated with DXR treatment. In fact, mouse 
body weight was less affected with respect to DXR alone 
both at 1.5 mg/kg and 2.5 mg/kg (data not shown). 
In summary, the reduced toxicity of DXR in 
OS sensitive (P-gp negative) cells under low pHe was 
independent of autophagy but apparently associated with 
an increased lysosomal acidification. Notably, this type 
of resistance develops within hours, in contrast to the 
expression of P-gp that occurs, according to the canonical 
model of MDR, after months of continuous exposure to 
DXR. To verify that resistance to DXR under short-term 
exposure to acidity is actually due to drug accumulation 
into lysosomes, we observed the intracellular fluorescence 
of DXR after 5–10 min of incubation. Surprisingly, DXR 
did not accumulate into the cell, a minor portion being 
compartmentalized into lysosomes. The high pH gradient 
generated between the acidic extracellular compartment 
and the alkaline cytosolic space is sufficient to affect 
the permeability to weak cationic drugs at the plasma 
membrane [51]. This occurs because uncharged, organic 
free bases are more permeable than their protonated 
charged counterparts and establish equal concentrations 
on both sides of the membrane. We therefore measured 
the difference between the extracellular and the cytosolic 
pH (pHe-pHi, ∆pHcm) at different pHe. Although the pHi 
was mildly acidified by the extracellular milieu, the net 
result was a strong alteration of ∆pHcm with a reversal of 
net charges. Notably, in Saos-2 cells, pre-treatment with 
OME slightly reduced this trend. Only a few reports have 
Figure 6: chemoresistant phenotypes of Os cells cultured at different pHe and treated with different drugs. Percentage 
of inhibition of cell viability of HOS cells cultured at pH 7.4, of P-gp expressing HOS cells (HOS 100-DXR), and of HOS cells cultured 
at pH 6.5 treated with different drugs, as measured by acid phosphatase assay after 72 h (*p < 0.05 vs HOS cells cultured at pH 7.4 and 
treated with the respective drug).
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linked pHi regulation also to drug resistance mediated by 
P-gp expression. MDR cells have been reported to have a 
more alkaline pHi [32, 52], and the magnitude of plasma 
membrane electrical potential decreases along with the 
increase of expression of P-gp [53]. According to this 
hypothesis, P-gp-mediated effects depend also on an altered 
regulation of ion transporters and signal transduction 
pathways (i.e., pH and membrane potential, key features 
necessary for the correct setting the biophysical parameters 
of the cells) [54]. In this context, P-gp has been suggested 
to work as a chloride channel, although it is yet unclear 
whether it might physically form a channel-like structure 
or rather regulate nearby anion transporters involved in the 
maintenance of pHi [53, 55, 56]. Here, we confirmed that 
P-gp expression in P-gp overexpressing OS cells obtained 
by continuous exposure to DXR [5] induces an alteration 
of ∆pHcm, that is partially reverted by verapamil. Moreover, 
we further verified that the anti P-gp monoclonal antibody 
MRK16, known to revert the MDR phenotype [57] 
completely abolished the ∆pHcm decrease observed under 
acidity. Therefore, according to our data, a change in ∆pHcm 
is necessary to induce chemoresistance, either by short-
term acidosis or by the long term drug exposure leading 
to P-gp expression. On this regard, the reversed ∆pHcm has 
been recently shown to interfere with the passage of drugs 
across the lipid bilayer of the cells, by altering the fluidity, 
the relative lipid density, and the surface tension of each of 
the leaflets within the membrane [33]. Short-term acidosis 
induced chemoresistance not only to DXR, but also to 
methotrexate, vincristine and, at a lesser extent, to cisplatin, 
other drugs commonly included in the standard therapeutic 
protocol for OS. 
concluding remarks
Altogether, our data provide evidence that the 
chemoresistant phenotype of OS is dependent on an 
inverted or altered ∆pHcm. This might rapidly result from 
the acidification of the TME  (Figure 7B), or derive from 
the induction of the expression of P-gp (Figure 7C). In this 
view, buffer therapies or proton pump inhibitors that block 
the abnormal ∆pHcm could be used in combination with 
standard anticancer agents. This hypothesis is supported 
by the encouraging results obtained in a pilot clinical study 
of human OS by the addition of esomeprazole to standard 
chemotherapy regimens [58]. Finally, the consistent 
evidence that changes of pHe strongly impact on the 
cytotoxicity of anticancer drugs should be taken into 
account. We therefore propose that in vitro IC50 assays 
for anticancer agents in sarcomas should always include a 
condition with an acidic medium in the range of pH 6.5-
6.8 to mimic the actual conditions of TME. 
MAtErIALs AND MEtHODs
cell lines
HOS, Saos-2, MG-63, and 143B human OS cell 
lines were purchased from the American Type Culture 
Collection, cultured in RPMI plus 20 units/mL penicillin, 
100 µg/mL streptomycin,  and 10% FCS at pH 7.4 
(complete medium), and incubated at 37°C in a humidified 
5% CO2 atmosphere. In assays with different pH, cells 
were seeded in complete medium, and after 24 h  media 
were changed. New media were set at a specific pH by 
Figure 7: ∆pHcm at the plasma membrane is an important player in Os chemoresistance. (A) When OS cells growth in a 
microenvironment with pHe 7.4 and with an unaffected system to maintain the pHi, DXR accumulates into the nucleus; (b) when OS cells 
growth in a microenvironment with pHe around 6.5, the ∆pHcm is reverted and DXR does enter into the cell. Only a very small fraction 
of DXR reaches the cytoplasm, and is immediately sequestered into lysosomes that, under this condition, are even more acidic; (c) when 
OS cells growth in a microenvironment with pHe 7.4 and express Pgp, the system to maintain the pHi is altered, membrane potential is 
reduced, and lysosomes are more acidic. As a result, although DXR can reach the cytoplasm, it is immediately sequestered into lysosomes.
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using different concentrations of sodium bicarbonate 
needed to preset pH in 5% CO2 atmosphere, according 
to the Henderson-Hasselbach equation. At the end-point 
of each experiment, the final pH in the supernatant was 
always measured by a digital pH-meter (pH 301, HANNA 
Instruments). To obtain HOS 100-DXR cells and MG-63 
MDR cells we continuously exposed parental cell lines 
to stepwise increases in DXR concentration (10-30-100 
ng/mL for HOS and 10-30 ng/mL for MG-63, Sigma). 
Approximately 2–3 weeks (4-5 passages) were required 
to establish adequate growth at each DXR concentration.
Growth assays
Cells were seeded in 6-well plates (100,000 cells/
well) in complete medium. After 24 h, the medium was 
changed with new complete medium at different pH, 
or with complete medium without sodium bicarbonate 
(unbuffered medium, UB), with or w/o DXR (15 ng/mL). 
The pH in UB condition, measured at all time points and 
for each cell line, was always 6.75 ± 0.07. Cell growth 
was evaluated by direct cell counting using the eritrosin 
dye (Sigma). Growth inhibition was obtained in respect to 
the untreated condition at the respective pH, and at a time 
point just after the specific doubling time at the considered 
pH (for HOS: 24 h at pH 7.4 and 8, 48 h at pH 6.5 and 
6.75; for Saos-2: 48 h at all the pH; for MG-63: 42 h at pH 
7.4 and 8, and 72 h at pH 6.5 and 6.75). The experiments 
were repeated three times, with two replicates for each 
assay. 
To calculate the IC50 values for DXR or to evaluate 
the growth inhibition of DXR treatment combined with 
pre-treatment with the proton-pump inhibitor omeprazole 
(OME), cells were seeded in 96-well plates (4,000 cells/
well) in complete medium. After 24 h, the medium was 
changed with new medium at different pH, with or w/o 
DXR (0-10-30-100-1000 ng/mL). For the combined 
treatment, 2 h before the change of media with DXR, cells 
were washed with PBS and incubated with medium 0.1 
% FCS with or w/o OME (210 μM, Sigma). After 72 h 
since the addition of DXR, the cell number was measured 
by an acid phosphatase assay, as previously described 
[59]. Briefly, the culture medium was removed, wells 
were washed with PBS, and 100 μl of buffer containing 
0.1 M sodium acetate (pH 5.0), 0.1% Triton X-100, and 
5 mM p-nitrophenil phosphate (Sigma) was added. After 
3 h at 37°C, the reaction was stopped with the addition 
of 10 μl of a 1 N NaOH, and color development was 
assayed at 405 nm using a microplate reader (Tecan 
Infinite F200pro). The experiment was repeated twice in 
quadruplicate. 
Similarly, to evaluate the percentage of inhibition 
of viability, cells were seeded in complete medium, 
and after additional 24 h, the medium was replaced 
with the respective conditions added with DXR 
100 ng/mL, or Cysplatin 250 ng/mL, or Methotrexate 
10 ng/mL, or Vincristine 100 ng/mL. After 72 h the cell 
number was measured by an acid phosphatase assay as 
described above. The experiment was repeated twice in 
quadruplicate. 
DXr uptake
According to the previously described method [60], 
cells were seeded at low density in a glass-bottom Petri 
dish (Inco), and incubated for 48 h in complete medium 
at different pH. Then, the medium was changed at the 
respective pH with DXR 10 μg/mL for 5 or 15 min. Cells 
were washed with PBS and maintained with drug-free 
complete medium at the respective pH. For quantitative 
determination of intranuclear DXR concentration, the 
laser (Exc wavelength 457.9 nm) was focused for 1 sec 
with a pinhole of 54 μm to the nucleus of cells to obtain 
fluorescence emission spectra. The drug concentration in 
the nuclei of living cells were obtained from the specific 
spectra contribution of DXR (Emi 560–590 nm). The 
analysis was performed using a TiE spectral confocal laser 
microscope (A1R, Nikon) equipped with a DS-QIMc-U2 
12 bit camera. We measured the fluorescence of 25 nuclei 
(within the nuclear perimeter) of 5 different random 
optical fields. DXR nuclear uptake was expressed as the 
mean of the sum of intensities divided by the nuclear 
area. The same experimental conditions and settings for 
confocal microscopy were also used for the acquisition of 
3D intensity embossed images.  
Western blotting
HOS cells were seeded in complete medium. 
After 24 h the medium was changed with new medium 
at different pH with or w/o DXR (10–100 mg/mL) for 
1 month to determine the level of P-gp expression. The 
medium was changed every 3–4 d, and confluent cells 
were trypsinized. Cells were treated in ice with 400 of lysis 
buffer [50 mM HEPES (pH 7.5), 150 mM NaCl, 1.5 mm 
MgCl2, 1 mM EGTA, 10% glycerol, 1% Triton X-100, 1% 
PMSF, 0.2 mM Na orthovanadate and 1% aprotinin, all 
from Sigma]. Protein concentration was determined with 
the Bradford protein assay (Bio-Rad). Total protein was 
separated on 6% gradient SDS-PAGE gel and transferred 
into nitrocellulose membranes. Blots were blocked 
with 5% nonfat dry milk in TBST and probed with the 
monoclonal P-gp (clone D-11), or TATA binding protein 
(TBP) rabbit antibodies (Santa Cruz Biotechnology). The 
secondary antibody was an anti-rabbit or anti-mouse IgG 
conjugated to horseradish peroxidase that was visualized 
by enhanced chemiluminescence detection reagents 
(Pierce). For the analysis of autophagy flux in HOS 
cells, PVDF membranes (GE Healthcare) were used and 
incubated with the following antibodies: rabbit polyclonal 
LC3B (Cell Signaling Technology), monoclonal β-actin 
(ACTB, clone AC-15) (Sigma), rabbit polyclonal ATG5 
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(Cell Signaling Technology), monoclonal SQSMT1 (clone 
3/P62 LCK LIGAND, BD Transduction laboratories), and 
rabbit DNA binding protein high mobility group box 1 
(HMGB1) (Cell Signaling Technology) antibodies.
Ultrastructural analysis
HOS cells cultured under acidic (pH 6.5) or standard 
(pH 7.4) conditions were washed in PBS and fixed with 
2.5 % glutaraldehyde in 0.1 M cacodylate buffer pH 
7.4 (Sigma) for 30 min at R°T, scraped, and pelletted at 
1,300 g for 20 min. Pellets were further fixed for 2 h. 
After washing in 0.1 M cacodylate buffer, samples were 
post-fixed with 1% osmium tetroxide in cacodylate buffer 
(Sigma) for 1 h at 4°C, dehydrated, and embedded in Epon 
resin. Ultrathin sections were stained with tannic acid, 
uranyl acetate and lead citrate, and observed with a Zeiss 
EM 109 transmission electron microscope. Image were 
captured using a Nikon digital camera (Dmx 1200F) and 
the ACT-1 software.
Lysosomal pH assays
Cells were cultured in complete medium at different 
pH for 48 h and then analyzed. Lysosensor staining: 
labeling and tracking of acidic organelles in living cells 
was performed by incubation with 1 μM LysoSensor 
Green DND-189 and 50 nM LysoTracker Red DND-99 
(Molecular Probes, Life Technologies) in medium at the 
respective pH. After 30 min at 37°C, cells were washed 
with fresh medium and observed by confocal microscopy 
(Nikon Eclipse E600).
Confocal spectral analysis: the emission spectra 
of the pH-sensitive dye AO was used to measure pH 
variations in acidic organelles, as previously described 
[61]. MG-63 cells were incubated with AO (0.5 μg/mL, 
Sigma) in medium at the respective pH for 15 min. After 
washing, x,y emission spectra from confocal sections of 
single living cells were recorded using a confocal laser 
microspectrofluorimeter (Nikon, TI) equipped with an 
argon-ion laser. Cells were focused with a ×40, 1.3 NA 
objective (S Fluor, Nikon), excited at 457 nm and the 
resulting fluorescence emission in the 500–700 nm range 
was collected. For intracellular measurements of AO 
emission the pinhole size was fixed to a diameter of 54 
μm. To characterize the profile of AO emission spectra, 
the red band contribution (R%) within the whole emission 











 are the green (520–540 nm) and 
the red (645-665 nm) integrated emission intensities, 
respectively. The R% was calculated for all the lysosomes 
within a single cell, and the average R% of lysosomes of 
single cells was considered. Average of the total number 
of all the lysosomes per single cell that were detectable 
by confocal microscopy analysis and AO staining was 
calculated out of 20 cells.
RNA extraction and RNA sequence analysis
Total RNA was extracted using guanidinium 
thiocyanate-phenol-chloroform from cell cultured 
under acidic (pH 6.5) or standard conditions (pH 7.4) 
for 24 h, and quantified by Bioanalyzer (Agilent, Santa 
Clara, CA) following the manufacturer’s instructions. 
RIN (RNA Integrity Number) and A260/A280 ratio 
of the prepared total RNA were all 10, and over 1.8, 
respectively. The library of template molecules for high 
throughput DNA sequencing was converted from the total 
RNA using TruSeq RNA Sample Prep Kit v2 (Illumina) 
following the manufacturer’s protocol. The library was 
quantified with Bioanalyzer (Agilent) following the 
manufacturer’s instruction. Library (7 pM) was subjected 
to cluster amplification to cluster generation on a Single 
Read Flow Cell v4 with a cluster generation instrument 
(Illumina). Sequencing was performed on a Genome 
Analyzer GAIIx for 76 cycles using Cycle Sequencing 
v4 regents (Illumina). Image analysis and base calling 
were performed using Off-Line Basecaller Software 
1.6 (Illumina). Reads were aligned using ELAND v2 of 
CASAVA Software 1.7 with the sequence data sets. Human 
genome build 19 (hg19) were downloaded from University 
of California, Santa Cruz genome browser (http://genome.
ucsc.edu/) as the analytic reference. Transcript coverage 
for every gene locus was calculated from the total number 
passing filter reads that mapped, by ELAND-RNA, to 
exons. These analyses were performed using default 
parameters. The advanced analysis for quantification 
with Quantile normalization algorithm was performed 
using Avadis NGS software (version1.5, Strand Scientific 
Intelligence Inc.). Filtering was performed using default 
parameters. All new data were deposited in DDBJ/EMBL/
GenBank under accession number DRA DRA004087.
Immunofluorescence
Before fixation, cells were incubated for 24 h 
at different pH, and then incubated with Lysotracker 
(0.25 μM) in medium at the respective pH for 30 min 
at 37°C. Cells were washed with PBS, fixed in 3% 
paraformaldehyde in PBS containing 300 mM sucrose 
(Sigma) for 20 min at 22°C. After washing with PBS, 
permeabilization was performed with 0.1% Triton X-100 
for 5 min. Then, cells were incubated with the anti-LC3B 
antibody (Santa Cruz Biotechnology), and with a solution 
containing anti-mouse Alexa green 488 nm (Molecular 
Probes, Life Technologies), and Hoechst 33258 (1.25 
μg/mL, Sigma) for the nuclear staining, and observed 
by confocal microscopy (Nikon TI-E). The staining was 
repeated two times.
Analysis of the autophagic flux
HOS cells were seeded at 200,000 cells/plate in 
6 cm tissue cultures dishes in standard RPMI medium. 
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After overnight incubation the medium was replaced with 
medium buffered at pH 7.4 or at pH 6.5 and cells were 
collected at different time points (4, 8, 24 and 48 h) after 
exposure to fresh media. For each time point, cells were 
treated or not with 50 nM bafilomycin A1 (BafA1) for 
2 h before collection. In some experiments, the lysosomal 
inhibitors pepstatin A and E64d were used at 10 mg/
ml. Analysis of the effects of DXR where performed by 
adding the drug (100 nM) for 24 h in the presence or 
absence of BafA1. The use of BafA1 to block lysosomal 
acidification was performed in order to analyze the rate of 
LC3 and SQTM1 degradation, indicative of the autophagic 
flux [36].
AtG5 silencing
HOS cells were seeded in 6-wells plates (50,000 
cells/well) in medium without antibiotics. The next day, 
cells were transfected with 25 nM siRNA for ATG5 
(Dharmacon RNA Technologies siGENOME SMART 
pool) and siRNA SCR (scrambled siRNA, control) using 
DharmaFECT-4 transfection reagent (Dharmacon), 
following the manufacturer’s instructions. The next day, 
the medium was changed with fresh complete medium 
buffered at different pH (7.4 and 6.5), with or without 
DXR (100 ng/mL). After 36 h, cells were collected and 
analyzed for apoptosis by Annexin V staining. Cells for 
Western blot analysis were collected at the same time. 
Four replicates were made for each assay.
Apoptosis assay
We evaluated apoptotic cell death by using 
Annexin-V staining (FITC Annexin V Apoptosis Detection 
Kit, BD Pharmingen) and by collecting green fluorescence 
in a FACSCalibur flow cytometer (Becton Dickinson) 
using the Cellquest Pro software. At least 10,000 cells/
sample were acquired and analyzed. The experiments were 
repeated five times, with two replicates for each assay.
In vivo studies
NOD/SCID animals were housed and maintained in 
a pathogen-free environment. 143B human cells (1 × 106) 
were subcutaneously injected with the reduced growth 
factor matrigel (BD, Bioscience) in the flank of 5 weeks 
old male mice (Charles River Laboratories International). 
Four days after the inoculation, mice were randomly 
separated into groups and assigned to pharmacological 
treatments (for each group n = 7). Both OME and 
DXR were reconstituted in saline solution and injected 
intraperitoneally (10 mg/kg and 1.5 mg/kg, respectively). 
Mice received saline solution, OME, DXR or a 
combination of OME and DXR, the latter being injected 
2 h after OME treatment. Weights were taken daily during 
treatment, and drug concentrations were recalculated to 
ensure that mice received a constant dose of OME and 
DXR. Treatments were repeated every 4 days and mice 
were sacrificed 18 days after tumor inoculation. Tumor 
size was estimated at every pharmacological treatment 
with a caliper and the weight was calculated by using the 
formula: tumor volume [mm3] = (length [mm] × width2 
[mm2])/2 [62]. For histological analysis, tumor xenografts 
were fixed in formalin and embedded in paraffin. 5 µm 
sections were stained with hematoxylin/eosin. The area of 
necrosis was quantified by NIS element image analysis 
software (Nikon). The Animal Ethics Committee of 
Modena has approved all the experimental protocols.
DXR intracellular content by flow cytometry 
quantification
HOS cells were seeded in 6-well plates (50,000 
cells/well) in complete medium. The next day, the medium 
was changed with fresh medium buffered at different pH 
(7.4 and 6.5), with or w/o DXR (50 ng/mL). After 24 and 
48 h, cells were collected and at least 10,000 cells/sample 
were analyzed by flow citometry. The mean fluorescence 
intensity (MFI) in the FL2 channel was evaluated by the 
DXR red fluorescence.
pH gradient at the plasma membrane
Cytosolic intracellular pH (pHi) of OS cells was 
measured by using carboxy-SNARF-1 and confocal 
microspectrofluorometry (Nikon, TI). Cells were seeded 
into glass Petri dishes and incubated for 48 h in medium at 
different pH. At the end, cells were additionally incubated 
in acidic pH (pH 6.5) for HOS, Saos-2, and MG-63 cells 
or in complete medium for HOS 100-DXR cells, with 
OME (210 mM) and Verapamil (500 μM), single treatment 
or combined, or with the MRK16 anti-MDR-1 antibody 
(10 m/mL). At the time of the analysis, cells were then 
treated with medium at the respective pH containing 
10 μM carboxy-SNARF-1 of the acetoxymethyl ester 
form (Molecular Probes, Life Technologies) at 37°C with 
5% CO2 for 30 min. Medium was replaced again with 
medium at the respective pH and Petri dishes were placed 
in an incubator (OkoLab), on the stage of the confocal 
microscope. We used an excitation laser of 514 nm 
wavelength (Argon) and a S Plan Fluor ELWD 40X lend 
(Nikon). The resulting fluorescence emissions at 644 nm 
and at 594 nm wavelengths were collected. Several regions 
of interest (ROI) were then randomly selected excluding 
nuclear regions. The emission ratio was calibrated using 
solutions (110 mM KCl, 25 mM KHCO3, 11 mM glucose, 
1 mM MgCl2, 1 mM CaCl2, 10 mM HEPES, Sigma) with 
varying pH (pH 6.5–8.0) that contained 10 μM nigericin 
(K+/H+ ionophore, Sigma). In this case, cells were allowed 
to adapt for at least 20 min before pHi measurements 
began. The fluorescence emission ratio (644 nm/594 nm) 
was calculated and used to estimate cytoplasmic pH from 
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the calibration curve of each cell line. Confocal images 
were processed using NIS Elements software (Nikon). We 
quantified 12 different random cells for each condition.
statistical analysis
Due to the small number of observations, data 
were considered as not normally distributed. Values 
were expressed as means ± SE. Statistical analysis was 
performed with the StatView 5.0.1 software (SAS Institute 
Inc., Cary, NC). The nonparametric Mann-Whitney U test 
was used and p < 0.05 was considered significant.
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